United Therapeutics (UTHR) Short-term Investments (2009 - 2026)

United Therapeutics (UTHR) has 18 years of Short-term Investments data on file, last reported at $874.0 million in Q1 2026.

• For the quarter ending Q1 2026, Short-term Investments fell 38.51% year-over-year to $874.0 million; the trailing twelve-month figure through Mar 2026 stood at $874.0 million (down 38.51% YoY), and the FY2025 full-year result was $1.4 billion, down 13.16% from the prior year.
• Short-term Investments eased to $874.0 million in Q1 2026, from $1.4 billion in the prior quarter.
• In the past five years, Short-term Investments ranged from a high of $1.9 billion in Q4 2022 to a low of $874.0 million in Q1 2026.
• A 5-year average of $1.5 billion and a median of $1.6 billion in 2024 frame the typical range for Short-term Investments.
• Across the five-year window, Short-term Investments jumped 81.24% in 2022 and sank 38.51% in 2026, its largest moves.
• Tracing UTHR's Short-term Investments over 5 years: stood at $1.9 billion in 2022, then slipped by 4.85% to $1.8 billion in 2023, then decreased by 12.12% to $1.6 billion in 2024, then decreased by 13.16% to $1.4 billion in 2025, then sank by 35.89% to $874.0 million in 2026.
• Business Quant data shows UTHR's Short-term Investments at $874.0 million in Q1 2026, $1.4 billion in Q4 2025, and $1.4 billion in Q3 2025.